Lineage Cell Therapeutics, Inc. (LCTX)
USD 0.5
(0.93%)
USD 0.5
(0.93%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -24.73 Million USD | -9.83% |
| 2022 | -22.52 Million USD | 54.24% |
| 2021 | -49.21 Million USD | -86.07% |
| 2020 | -26.44 Million USD | 31.97% |
| 2019 | -38.87 Million USD | 6.98% |
| 2018 | -41.79 Million USD | -7.44% |
| 2017 | -38.9 Million USD | 34.03% |
| 2016 | -58.96 Million USD | 10.4% |
| 2015 | -65.8 Million USD | -29.85% |
| 2014 | -50.68 Million USD | 9.47% |
| 2013 | -55.98 Million USD | -123.93% |
| 2012 | -25 Million USD | -33.79% |
| 2011 | -18.68 Million USD | -89.67% |
| 2010 | -9.85 Million USD | -179.87% |
| 2009 | -3.52 Million USD | -24.72% |
| 2008 | -2.82 Million USD | -130.91% |
| 2007 | -1.22 Million USD | 30.22% |
| 2006 | -1.75 Million USD | 13.21% |
| 2005 | -2.01 Million USD | -2.52% |
| 2004 | -1.96 Million USD | -16.51% |
| 2003 | -1.68 Million USD | 16.95% |
| 2002 | -2.03 Million USD | 41.78% |
| 2001 | -3.49 Million USD | 31.35% |
| 2000 | -5.09 Million USD | 11.62% |
| 1999 | -5.75 Million USD | -174.27% |
| 1998 | -2.1 Million USD | 34.38% |
| 1997 | -3.2 Million USD | -60.0% |
| 1996 | -2 Million USD | 20.0% |
| 1995 | -2.5 Million USD | -56.25% |
| 1994 | -1.6 Million USD | -23.08% |
| 1993 | -1.3 Million USD | -85.71% |
| 1992 | -700 Thousand USD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | -5.86 Million USD | 11.92% |
| 2024 Q1 | -6.66 Million USD | -4.7% |
| 2023 Q1 | -6.64 Million USD | -0.05% |
| 2023 Q4 | -6.36 Million USD | 5.12% |
| 2023 Q2 | -5.02 Million USD | 24.36% |
| 2023 Q3 | -6.7 Million USD | -33.46% |
| 2023 FY | -24.73 Million USD | -9.83% |
| 2022 FY | -22.52 Million USD | 54.24% |
| 2022 Q3 | -5.25 Million USD | -24.02% |
| 2022 Q4 | -6.63 Million USD | -26.43% |
| 2022 Q1 | -6.39 Million USD | 77.35% |
| 2022 Q2 | -4.23 Million USD | 33.8% |
| 2021 Q3 | -6.84 Million USD | 3.35% |
| 2021 FY | -49.21 Million USD | -86.07% |
| 2021 Q4 | -28.23 Million USD | -312.66% |
| 2021 Q1 | -7.05 Million USD | -19.86% |
| 2021 Q2 | -7.08 Million USD | -0.43% |
| 2020 Q3 | -6.72 Million USD | -5.05% |
| 2020 FY | -26.44 Million USD | 31.97% |
| 2020 Q1 | -7.43 Million USD | -8.24% |
| 2020 Q4 | -5.88 Million USD | 12.54% |
| 2020 Q2 | -6.4 Million USD | 13.93% |
| 2019 Q1 | -12.76 Million USD | -26.26% |
| 2019 Q3 | -8.42 Million USD | 22.17% |
| 2019 Q4 | -6.87 Million USD | 18.4% |
| 2019 FY | -38.87 Million USD | 6.98% |
| 2019 Q2 | -10.82 Million USD | 15.2% |
| 2018 Q3 | -10.35 Million USD | -13.27% |
| 2018 FY | -41.79 Million USD | -7.44% |
| 2018 Q1 | -12.18 Million USD | -27.44% |
| 2018 Q4 | -10.1 Million USD | 2.41% |
| 2018 Q2 | -9.14 Million USD | 24.97% |
| 2017 Q1 | -11.26 Million USD | -0.08% |
| 2017 FY | -38.9 Million USD | 34.03% |
| 2017 Q4 | -9.56 Million USD | -0.53% |
| 2017 Q2 | -10.31 Million USD | 8.38% |
| 2017 Q3 | -9.51 Million USD | 7.8% |
| 2016 Q4 | -11.25 Million USD | -17.77% |
| 2016 Q1 | -23.75 Million USD | -9.48% |
| 2016 Q2 | -14.4 Million USD | 39.38% |
| 2016 Q3 | -9.55 Million USD | 33.66% |
| 2016 FY | -58.96 Million USD | 10.4% |
| 2015 Q1 | -13.5 Million USD | 6.27% |
| 2015 Q2 | -13.49 Million USD | 0.04% |
| 2015 Q4 | -21.7 Million USD | -26.87% |
| 2015 FY | -65.8 Million USD | -29.85% |
| 2015 Q3 | -17.1 Million USD | -26.73% |
| 2014 Q2 | -13.06 Million USD | -17.27% |
| 2014 Q3 | -12.13 Million USD | 7.07% |
| 2014 Q4 | -14.4 Million USD | -18.68% |
| 2014 Q1 | -11.13 Million USD | 61.98% |
| 2014 FY | -50.68 Million USD | 9.47% |
| 2013 Q3 | -10.2 Million USD | -25.69% |
| 2013 Q2 | -8.11 Million USD | 3.14% |
| 2013 Q1 | -8.37 Million USD | -18.72% |
| 2013 FY | -55.98 Million USD | -123.93% |
| 2013 Q4 | -29.29 Million USD | -187.14% |
| 2012 Q2 | -6.07 Million USD | -2.77% |
| 2012 Q1 | -5.91 Million USD | -8.34% |
| 2012 FY | -25 Million USD | -33.79% |
| 2012 Q3 | -5.94 Million USD | 2.18% |
| 2012 Q4 | -7.05 Million USD | -18.7% |
| 2011 Q3 | -4.23 Million USD | -184.97% |
| 2011 Q1 | -4.02 Million USD | -7.21% |
| 2011 Q2 | 4.98 Million USD | 223.72% |
| 2011 Q4 | -5.46 Million USD | -29.01% |
| 2011 FY | -18.68 Million USD | -89.67% |
| 2010 Q3 | -2.45 Million USD | -6.14% |
| 2010 Q1 | -1.32 Million USD | -176.48% |
| 2010 FY | -9.85 Million USD | -179.87% |
| 2010 Q2 | -2.31 Million USD | -74.6% |
| 2010 Q4 | -3.75 Million USD | -52.79% |
| 2009 Q1 | -911.25 Thousand USD | 5.86% |
| 2009 Q2 | -1.1 Million USD | -21.55% |
| 2009 Q4 | 1.73 Million USD | 159.09% |
| 2009 Q3 | -2.93 Million USD | -164.92% |
| 2009 FY | -3.52 Million USD | -24.72% |
| 2008 Q4 | -968.02 Thousand USD | -5.93% |
| 2008 Q1 | -407.07 Thousand USD | -58.15% |
| 2008 Q3 | -913.85 Thousand USD | 3.74% |
| 2008 Q2 | -949.33 Thousand USD | -133.21% |
| 2008 FY | -2.82 Million USD | -130.91% |
| 2007 Q4 | -257.39 Thousand USD | -65.35% |
| 2007 Q2 | -293.79 Thousand USD | 43.02% |
| 2007 Q1 | -515.63 Thousand USD | -51.6% |
| 2007 FY | -1.22 Million USD | 30.22% |
| 2007 Q3 | -155.66 Thousand USD | 47.02% |
| 2006 Q2 | -641.18 Thousand USD | -39.06% |
| 2006 Q4 | -340.12 Thousand USD | -9.9% |
| 2006 Q3 | -309.49 Thousand USD | 51.73% |
| 2006 Q1 | -461.07 Thousand USD | 0.2% |
| 2006 FY | -1.75 Million USD | 13.21% |
| 2005 FY | -2.01 Million USD | -2.52% |
| 2005 Q1 | -725.52 Thousand USD | -21.05% |
| 2005 Q2 | -427.17 Thousand USD | 41.12% |
| 2005 Q3 | -403.7 Thousand USD | 5.5% |
| 2005 Q4 | -462.01 Thousand USD | -14.44% |
| 2004 Q4 | -599.37 Thousand USD | -44.1% |
| 2004 Q1 | -505.49 Thousand USD | -35.18% |
| 2004 Q2 | -447.94 Thousand USD | 11.39% |
| 2004 Q3 | -415.95 Thousand USD | 7.14% |
| 2004 FY | -1.96 Million USD | -16.51% |
| 2003 Q1 | -465.68 Thousand USD | 23.53% |
| 2003 FY | -1.68 Million USD | 16.95% |
| 2003 Q3 | -357.32 Thousand USD | 27.5% |
| 2003 Q2 | -492.87 Thousand USD | -5.84% |
| 2003 Q4 | -373.94 Thousand USD | -4.65% |
| 2002 Q3 | -317.59 Thousand USD | 44.6% |
| 2002 Q4 | -609 Thousand USD | -91.75% |
| 2002 FY | -2.03 Million USD | 41.78% |
| 2002 Q1 | -534.74 Thousand USD | -23.5% |
| 2002 Q2 | -573.28 Thousand USD | -7.21% |
| 2001 Q2 | -1.12 Million USD | -17.45% |
| 2001 Q1 | -958.19 Thousand USD | 7.9% |
| 2001 Q3 | -934.08 Thousand USD | 17.0% |
| 2001 FY | -3.49 Million USD | 31.35% |
| 2001 Q4 | -432.97 Thousand USD | 53.65% |
| 2000 Q3 | -1.28 Million USD | 6.76% |
| 2000 FY | -5.09 Million USD | 11.62% |
| 2000 Q1 | -1.38 Million USD | 5.09% |
| 2000 Q2 | -1.37 Million USD | 0.47% |
| 2000 Q4 | -1.04 Million USD | 19.08% |
| 1999 Q2 | -1.1 Million USD | -37.5% |
| 1999 Q1 | -800 Thousand USD | 0.0% |
| 1999 FY | -5.75 Million USD | -174.27% |
| 1999 Q4 | -1.45 Million USD | 36.53% |
| 1999 Q3 | -2.3 Million USD | -109.09% |
| 1998 Q1 | -1.2 Million USD | -50.0% |
| 1998 FY | -2.1 Million USD | 34.38% |
| 1998 Q3 | -1.2 Million USD | -71.43% |
| 1998 Q2 | -700 Thousand USD | 41.67% |
| 1997 FY | -3.2 Million USD | -60.0% |
| 1997 Q1 | -500 Thousand USD | 28.57% |
| 1997 Q4 | -800 Thousand USD | 27.27% |
| 1997 Q3 | -1.1 Million USD | 8.33% |
| 1997 Q2 | -1.2 Million USD | -140.0% |
| 1996 Q2 | -2.1 Million USD | -2200.0% |
| 1996 Q3 | -600 Thousand USD | 71.43% |
| 1996 Q4 | -700 Thousand USD | -16.67% |
| 1996 FY | -2 Million USD | 20.0% |
| 1996 Q1 | 100 Thousand USD | 0.0% |
| 1995 Q3 | -200 Thousand USD | 75.0% |
| 1995 Q4 | 100 Thousand USD | 150.0% |
| 1995 Q2 | -800 Thousand USD | -60.0% |
| 1995 Q1 | -500 Thousand USD | 16.67% |
| 1995 FY | -2.5 Million USD | -56.25% |
| 1994 Q1 | -200 Thousand USD | 33.33% |
| 1994 FY | -1.6 Million USD | -23.08% |
| 1994 Q3 | -400 Thousand USD | 33.33% |
| 1994 Q2 | -600 Thousand USD | -200.0% |
| 1994 Q4 | -600 Thousand USD | -50.0% |
| 1993 Q1 | -200 Thousand USD | 33.33% |
| 1993 Q3 | -300 Thousand USD | 25.0% |
| 1993 Q4 | -300 Thousand USD | 0.0% |
| 1993 FY | -1.3 Million USD | -85.71% |
| 1993 Q2 | -400 Thousand USD | -100.0% |
| 1992 Q2 | -400 Thousand USD | -300.0% |
| 1992 FY | -700 Thousand USD | 0.0% |
| 1992 Q4 | -300 Thousand USD | -50.0% |
| 1992 Q1 | -100 Thousand USD | 0.0% |
| 1992 Q3 | -200 Thousand USD | 50.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| AIM ImmunoTech Inc. | -31.91 Million USD | 22.506% |
| Ampio Pharmaceuticals, Inc. | -9.51 Million USD | -159.855% |
| Armata Pharmaceuticals, Inc. | -40.89 Million USD | 39.513% |
| Actinium Pharmaceuticals, Inc. | -51.92 Million USD | 52.363% |
| Azitra, Inc. | -7.61 Million USD | -224.734% |
| Can-Fite BioPharma Ltd. | -8.19 Million USD | -201.806% |
| Chromocell Therapeutics Corporation | -6.86 Million USD | -260.419% |
| Calidi Biotherapeutics, Inc. | -28.99 Million USD | 14.69% |
| CEL-SCI Corporation | -31.47 Million USD | 21.423% |
| iBio, Inc. | -16.63 Million USD | -48.689% |
| MAIA Biotechnology, Inc. | -20.18 Million USD | -22.547% |
| Matinas BioPharma Holdings, Inc. | -23.76 Million USD | -4.069% |
| Navidea Biopharmaceuticals, Inc. | -14.05 Million USD | -76.024% |
| NovaBay Pharmaceuticals, Inc. | -5 Million USD | -394.363% |
| NanoViricides, Inc. | -8.51 Million USD | -190.426% |
| Oragenics, Inc. | -20.9 Million USD | -18.312% |
| BiomX Inc. | -27.68 Million USD | 10.663% |
| BiomX Inc. | -27.68 Million USD | 10.663% |
| Protalix BioTherapeutics, Inc. | 10.46 Million USD | 336.453% |
| Palatin Technologies, Inc. | -22.49 Million USD | -9.943% |
| Scorpius Holdings, Inc. | -42.03 Million USD | 41.157% |